Status:
UNKNOWN
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
Lead Sponsor:
Command Hospital, India
Conditions:
Fatty Liver
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Non Alcoholic Fatty Liver Disease (NAFLD) is considered as the component of metabolic syndrome. The prevalence of the same has been increasing rapidly in India, along with an increase in the prevalenc...
Detailed Description
The therapeutic options for the management of nonalcoholic fatty liver disease (NAFLD) include lifestyle modifications, insulin sensitizers, vitamin E, antioxidants and cytoprotective agents. Glitazon...
Eligibility Criteria
Inclusion
- Drug naive patients with NAFLD diagnosed on ultrasonography, BMI \> 23 kg/m2 and ALT \> 1.5 times the upper limit of normal
Exclusion
- Use of any drugs other than lifestyle modification for NAFLD, HbA1c \> 8% FBS\>200, Bilirubin \> 1.5 mg/dL
- Any illness likely to cause transaminitis and positive viral markers
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2015
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02265276
Start Date
October 1 2014
End Date
September 1 2015
Last Update
October 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Command Hospital
Panchkula, Haryana, India, 134107